The TAILOR-RT Phase III is randomizing patients to regional nodal radiation that have ER+/Her2-negative biomarker low risk (defined as Oncotype ≤ 25) breast cancers with low lymph node burden (1–3+ lymph nodes) [78]. Here, ESR1 is linked to breast cancer.